Immatics Announces Collaboration With Moderna

Reston – September 11, 2023 – Cooley advised Immatics, a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, on its strategic collaboration with Moderna. Lawyers Kenneth Krisko and Stephanie Palmer led the Cooley team advising Immatics.

The collaboration combines Immatics’ T cell receptor (TCR) platform with Moderna’s cutting-edge mRNA technology. Immatics will receive an upfront payment of $120 million, and the company is eligible to receive development, regulatory and commercial milestone payments that could exceed $1.7 billion.

Cooley previously advised Immatics on its collaborations with Bristol Myers Squibb in June 2022 and December 2021, and its collaboration with Roche in December 2013.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.

Cooley has nearly 1,400 lawyers across 18 offices in the United States, Asia and Europe, and a total workforce of more than 3,000.